UAB Digital Repository of Documents 8 records found  Search took 0.01 seconds. 
1.
13 p, 2.7 MB Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition / Winkler, R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mägdefrau, A.S. (Friedrich Schiller University Jena) ; Piskor, E.M. (Friedrich Schiller University Jena) ; Kleemann, M. (Friedrich Schiller University Jena) ; Beyer, M. (University Medical Center Mainz) ; Linke, K. (Friedrich Schiller University Jena) ; Hansen, L. (Friedrich Schiller University Jena) ; Schaffer, A.M. (Friedrich Schiller University Jena) ; Hoffmann, M.E. (Institute of Molecular Biology) ; Poepsel, S. (University of Cologne) ; Heyd, F. (Freie Universität Berlin) ; Beli, P. (Institute of Molecular Biology) ; Möröy, T. (Institut de Recherches Cliniques de Montréal) ; Mahboobi, S. (University of Regensburg) ; Krämer, O.H. (University Medical Center Mainz) ; Kosan, C. (Friedrich Schiller University Jena) ; Universitat Autònoma de Barcelona
Overexpression of MYC is a genuine cancer driver in lymphomas and related to poor prognosis. However, therapeutic targeting of the transcription factor MYC remains challenging. Here, we show that inhibition of the histone deacetylase 6 (HDAC6) using the HDAC6 inhibitor Marbostat-100 (M-100) reduces oncogenic MYC levels and prevents lymphomagenesis in a mouse model of MYC-induced aggressive B-cell lymphoma. [...]
2022 - 10.1038/s41388-022-02450-3
Oncogene, Vol. 41 Núm. 40 (30 2022) , p. 4560-4572  
2.
16 p, 5.4 MB Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression / Mota, Alba (Universidad Autónoma de Madrid. Departamento de Bioquímica) ; Oltra, Sara S. (Centro de Investigación Biomédica en Red de Cáncer) ; Selenica, Pier (Memorial Sloan Kettering Cancer Center) ; Moiola, Cristian Pablo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Casas-Arozamena, Carlos (Instituto de Investigación Sanitaria de Santiago (IDIS)) ; López-Gil, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Diaz, Eva (MD Anderson International Foundation) ; Gatius, Sonia (Hospital Arnau de Vilanova (València)) ; Ruiz-Miro, María (Biobank (Lleida)) ; Calvo, Ana (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Rojo-Sebastián, Alejandro (MD Anderson Cancer Center) ; Hurtado Blanco, P (Instituto de Investigación Sanitaria de Santiago (IDIS)) ; Piñeiro, Health Research Institute of Santiago de Compostela ; Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ; Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center.) ; Muinelo-Romay, Laura (Instituto de Investigación Sanitaria de Santiago (IDIS)) ; Abal Posada, Miguel (Instituto de Investigación Sanitaria de Santiago (IDIS)) ; Matias-Guiu, Xavier (Universitat de Lleida) ; Weigelt, Britta (Memorial Sloan Kettering Cancer Center. Department of Pathology) ; Moreno-Bueno, Gema (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). [...]
2022 - 10.1038/s41388-022-02221-0
Oncogene, Vol. 41 (february 2022) , p. 1835-1850  
3.
7 p, 979.5 KB Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer / Piqué, L. (Institut d'Investigació Biomèdica de Bellvitge) ; Martinez de Paz, A. (Institut d'Investigació Biomèdica de Bellvitge) ; Piñeyro, David (Institut d'Investigació Biomèdica de Bellvitge) ; Martínez Cardús, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Castro de Moura, Manuel (Institut d'Investigació Biomèdica de Bellvitge) ; Llinàs-Arias, Pere (Institut d'Investigació Biomèdica de Bellvitge) ; Setien, F. (Institut d'Investigació Biomèdica de Bellvitge) ; Gómez-Miragaya, Jorge (Institut d'Investigació Biomèdica de Bellvitge) ; Gonzalez-Suarez, Eva (Institut d'Investigació Biomèdica de Bellvitge) ; Sigurdsson, S. (Department of Biochemistry and Molecular Biology. Biomedical Center) ; Jonasson, J. G. (Landspitali University Hospital (Reykjavík, Islàndia)) ; Villanueva, Alberto (Institut Català d'Oncologia) ; Vidal, A. (Hospital Universitari de Bellvitge) ; Davalos, Veronica (Institut d'Investigació Biomèdica de Bellvitge) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. [...]
2019 - 10.1038/s41388-019-0936-x
Oncogene, Vol. 38 Núm. 45 (july 2019) , p. 7106-7112  
4.
43 p, 3.9 MB LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells / Cebrià Costa, Joan Pau (Vall d'Hebron Institut d'Oncologia) ; Pascual Reguant, Laura (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Institute for Research in Biomedicine (IRB Barcelona)) ; Serra-Bardenys, Gemma (Vall d'Hebron Institut d'Oncologia) ; Querol, Jessica (Vall d'Hebron Institut d'Oncologia) ; Cosín Tomás, Marc (Vall d'Hebron Institut d'Oncologia) ; Verde, Gaetano (Universitat Internacional de Catalunya. Facultat de Ciències de la Salut) ; Aiese Cigliano, Riccardo (Sequentia Biotech SL) ; Sanseverino, Walter. (Sequentia Biotech SL) ; Segura-Bayona, Sandra (Institute for Research in Biomedicine (IRB Barcelona)) ; Iturbide, Ane (Institute of Epigenetics and Stem Cells) ; Andreu Martínez, David (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Nuciforo, Paolo. (Vall d'Hebron Institut d'Oncologia) ; Bernadó Morales, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ; Rodilla, Verónica (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Yélamos, José (Institut Hospital del Mar d'Investigacions Mèdiques) ; Garcia de Herreros, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques) ; Stracker, Travis H. (Institute for Research in Biomedicine (IRB Barcelona)) ; Peiró, Sandra (Vall d'Hebron Institut d'Oncologia)
Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. [...]
2020 - 10.1038/s41388-019-0969-1
Oncogene, Vol. 39 (2020) , p. 79-121  
5.
23 p, 3.8 MB Connexins in cancer : bridging the gap to the clinic / Aasen, Trond (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Leithe, Edward (Oslo University Hospital. Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital and K.G. Jebsen Colorectal Cancer Research Centre) ; Graham, Sheila V. (University of Glasgow. MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences) ; Kameritsch, Petra (Ludwig-Maximilians-Universität München and Munich University Hospital. Walter Brendel Centre of Experimental Medicine) ; Mayán, María D. (University of A Coruña. CellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de Saúde (SERGAS)) ; Mesnil, Marc (Université de Poitiers. STIM Laboratory, Faculté des Sciences Fondamentales et Appliquées) ; Pogoda, Kristin (Ludwig-Maximilians-Universität München and Munich University Hospital. Walter Brendel Centre of Experimental Medicine) ; Tabernero, Arantxa (Universidad de Salamanca. Departamento de Bioquímica y Biología Molecular) ; Universitat Autònoma de Barcelona
Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. [...]
2019 - 10.1038/s41388-019-0741-6
Oncogene, Vol. 38 (february 2019) , p. 4429-4451  
6.
12 p, 4.3 MB Beyond molecular tumor heterogeneity : protein synthesis takes control / Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hümmer, Stefan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pelletier, Jerry (Montreal, QC Canada) ; Sonenberg, Nahum (Montreal, QC Canada) ; Universitat Autònoma de Barcelona
One of the daunting challenges facing modern medicine lies in the understanding and treatment of tumor heterogeneity. Most tumors show intra-tumor heterogeneity at both genomic and proteomic levels, with marked impacts on the responses of therapeutic targets. [...]
2018 - 10.1038/s41388-018-0152-0
Oncogene, Vol. 37 (february 2018) , p. 2490-2501  
7.
12 p, 4.1 MB ΔNp63α promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82 / Di Giacomo, V (Centre de Regulació Genòmica) ; Tian, T. V (Centre de Regulació Genòmica) ; Mas, A. (Centre de Regulació Genòmica) ; Pecoraro, M. (Centre de Regulació Genòmica) ; Batlle Morera, Laura (Centre de Regulació Genòmica) ; Noya, L. (Universitat Autònoma de Barcelona. Centre de Biotecnologia Animal i de Teràpia Gènica (CBATEG)) ; Martín-Caballero, J. (Parc de Recerca Biomèdica de Barcelona (PRBB)) ; Ruberte, J. (Universitat Autònoma de Barcelona. Centre de Biotecnologia Animal i de Teràpia Gènica (CBATEG)) ; Keyes, W. M. (Max Planck Institute of Biochemistry)
ΔNp63α is a critical mediator of epithelial development and stem cell function in a variety of tissues including the skin and breast, while overexpression of ΔNp63α acts as an oncogene to drive tumor formation and cancer stem cell properties in squamous cell carcinoma. [...]
2017 - 10.1038/onc.2017.42
Oncogene, Vol. 36 (04 2017) , p. 4381-4392  
8.
21 p, 1.8 MB Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma / Rodriguez Blanco, J. (University of Miami. Miller School of Medicine) ; Pednekar, L. (University of Miami. Miller School of Medicine) ; Penas Pérez, Clara (University of Miami. Miller School of Medicine) ; Li, B. (University of Miami. Miller School of Medicine) ; Martin, V. (Universidad de Oviedo. Departamento de Morfología y Biología Celular) ; Long, J. (University of Miami. Miller School of Medicine) ; Lee, E. (Department of Cell and Developmental Biology, Vanderbilt University) ; Weiss, WA. (Department of Neurobiology, University of California) ; Rodriguez, C. (Universidad de Oviedo. Departamento de Morfología y Biología Celular) ; Mehrdad, N. (University of Miami, Miller School of Medicine) ; Nguyen, DM. (University of Miami, Miller School of Medicine) ; Ayad, N. G (University of Miami. Miller School of Medicine) ; Rai, P. (University of Miami, Miller School of Medicine) ; Capobianco, AJ. (University of Miami. Miller School of Medicine) ; Robbins, D. J. (University of Miami. Miller School of Medicine)
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. [...]
2017 - 10.1038/onc.2017.232
Oncogene, Vol. Epub (2017)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.